NeuroSense Therapeutics (NRSN) EBT (2021 - 2024)
NeuroSense Therapeutics (NRSN) posted EBT of $18.6 million for Q4 2024, up 226.92% sequentially from -$14.7 million in Q3 2024, and up 684.22% YoY from $2.4 million in Q1 2024.
NeuroSense Therapeutics (NRSN) EBT (2021 - 2024) Analysis & Trends
NeuroSense Therapeutics has reported EBT for 4 years, with the latest figure at $18.6 million in Q4 2024.
- Quarterly EBT rose 684.22% year-over-year to $18.6 million in Q4 2024, while the trailing twelve-month figure through Dec 2024 was $10.2 million (up 201.02% YoY) and the FY2025 annual result came in at $11.1 million, up 8.96% from the prior year.
- EBT advanced to $18.6 million in Q4 2024 per NRSN's latest filing, from -$14.7 million in the prior quarter.
- Over five years, EBT peaked at $19.7 million in Q4 2022 and troughed at -$15.4 million in Q3 2022.
- A 4-year average of $1.6 million and a median of -$1.5 million in 2022 frame the typical range for EBT.
- The widest YoY moves for EBT: up 684.22% in 2024, down 4091.43% in 2024.
- Over 4 years, EBT stood at $7.2 million in 2021, then soared by 174.89% to $19.7 million in 2022, then tumbled by 116.19% to -$3.2 million in 2023, then surged by 684.22% to $18.6 million in 2024.
- According to Business Quant data, EBT over the past three periods registered $18.6 million, -$14.7 million, and $11.7 million for Q4 2024, Q3 2024, and Q2 2024 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBT (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.83 Bn | 130.98 Bn | 2.84 Bn | 1.39 Bn |
| 2 | Regeneron Pharmaceuticals | 85.79 Bn | 77.79 Bn | 3.93 Bn | 1.53 Bn |
| 3 | Argenx Se | 64.95 Bn | 59.77 Bn | 1.37 Bn | 541.00 Mn |
| 4 | Moderna | 58.59 Bn | 53.46 Bn | 52.00 Mn | -767.00 Mn |
| 5 | BeOne Medicines | 41.93 Bn | 36.83 Bn | 1.53 Bn | 312.46 Mn |
| 6 | Alnylam Pharmaceuticals | 31.52 Bn | 28.21 Bn | 992.69 Mn | 177.81 Mn |
| 7 | BioNTech SE | 27.98 Bn | 9.58 Bn | 668.28 Mn | -264.70 Mn |
| 8 | Insmed | 27.42 Bn | 26.26 Bn | 358.27 Mn | -11.37 Mn |
| 9 | Royalty Pharma | 27.33 Bn | 26.49 Bn | - | 81.49 Mn |
| 10 | NeuroSense Therapeutics | 9.94 Mn | 9.72 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2024 | 18.62 Mn |
| Sep 30, 2024 | -14.67 Mn |
| Jun 30, 2024 | 11.67 Mn |
| Mar 31, 2024 | -5.40 Mn |
| Dec 31, 2023 | -3.19 Mn |
| Sep 30, 2023 | -350,000.00 |
| Jun 30, 2023 | -3.65 Mn |
| Mar 31, 2023 | -2.92 Mn |
| Dec 31, 2022 | 19.68 Mn |
| Sep 30, 2022 | -15.39 Mn |
| Jun 30, 2022 | 8.91 Mn |
| Mar 31, 2022 | -2.72 Mn |
| Dec 31, 2021 | 7.16 Mn |
| Jun 30, 2021 | 5.18 Mn |